Trubion, Facet Collaborate on Leukemia Drug

Facet Biotech Corporation and Trubion Pharmaceuticals announce an agreement for the joint worldwide development and commercialization of TRU-016, a product candidate in phase 1 clinical development for chronic lymphocytic leukemia.
MSN Money